Consistently contributing to the information available to pain physicians and patients is a high priority for Dr. Webster. Publishing literary works in a variety of prestigious publications with large reader bases is one of the many ways he is able to do this. Dr. Webster’s work has been featured in more than 150 scientific peer-reviewed journal articles and over 250 abstracts over the course of his career. Below, you’ll find a list of his most recent publications.

Scientific Journal Articles

  1. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid risk tool. Pain Medicine 2005;6(6):432-42.
  2. Webster LR. Methadone-related deaths. Journal of Opioid Management. 2005;1(4):211-17.
  3. Rauck RL, Wallace MS, Leong MS, MineHart M, Webster LR, Charapata SG, Abraham JE, Buffington DE, Ellis D, Kartzinel R. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. Journal of Pain and Symptom Management. 2005;31(5):393-406.
  4. Webster LR. Fentanyl buccal tablets. Expert Opinion On Investigational Drugs. 2006;15(11):1469-73.
  5. Webster LR, Walker MJ. Safety and efficacy of prolonged outpatient ketamine infusions for neuropathic pain. American Journal of Therapeutics. 2006;13(4):300-5.
  6. Webster LR. Pharmaceutical management of cancer breakthrough pain. US Oncological Disease. 2006;1(2):102-3.
  7. Webster LR, Fakata K, Charapata S, Fisher R, MineHart M. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Medicine. 2008;9(3):282-90.
  8. Webster L, Jansen J, Peppin JB Lasko B, Irving B, Morlion B, Snidow J, Pierce A, Mortensen E, Kleoudis C, Carter E.  Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008;137(2):428-40.
  9. Webster LR. Breakthrough pain in the management of chronic persistent pain syndromes. The American Journal of Managed Care. 2008;14(5 suppl 1):S116-22.
  10. Webster LR. Pharmacogentics in pain management: the clinical need. Clinics in Laboratory Medicine. 2008;28(4):569-79.
  11. Webster LR, Choi Y, Desai H, Grant BJB. Sleep-disordered breathing and chronic opioid therapy. Pain Medicine. 2008;9(4):425-32.
  12. Webster LR. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Medicine. 2009; 10(S2):S124-S133.
  13. Couto JE, Webster LR, Romney MC, Leider HL, Linden A. Use of an algorithm applied to urine drug screening to assess adherence to an oxycontin regimen. Journal of Opioid Management. 2009;5(6):359-64.
  14. Webster LR. The question of opioid euphoriaDrug Discovery and Development.  July 30, 2009.
  15. Chapman CR, Lipschitz DL, Angst MS, Chou R, Denisco RC, Donaldson GW, Fine PG, Foley KM, Gallagher RM, Gilson AM, Haddox JD, Horn SD, Inturrisi CE, Jick SS, Lipman AG, Loeser JD, Noble M, Porter L, Rowbotham MC, Schoellas KM, Turk DC, Volinn E, Von Korff MR, Webster LR, Weisner CM.  Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-baseJournal of Pain.  2010;11(9):807-29.
  16. Webster LR, Fine PG. Approaches to improve pain relief while minimizing opioid abuse liability. Journal of Pain. 2010;11(7):602-11
  17. Webster LR, Malan TP, Tuchman MM, Mollen MD, Tobias JK, Vanhove GF.  A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch for the treatment of postherpetic neuralgia. Journal of Pain. 2010;11(10):972-82.
  18. Webster LR, Tark M, Rauck R, Tobias JK, Vanhove GF. Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia. BMC Neurology. 2010;10:92.
  19. Wang H, Gargano C, Lukac S, Jackson A, Beals C, Smiley P, Drexel M, Ruddy M, Herman G, Johnson-Levonas AO, Medve R, Webster L, Reicin A. An enhanced bunionectomy model as a potential tool for early decision-making in the development of new analgesics. Advances in Therapy. 2010;27(12):963-80.
  20. Webster LR, Cochella S, Dasgupta N, Fakata KL, Fine PG, Fishman SM, Grey T, Johnson EM, Lee LK, Passik SD, Peppin J, Porucznik CA, Ray A, Schnoll SH, Stieg RL, Wakeland W.  An analysis of the root causes for opioid-related deaths in the United States. Pain Medicine. 2011;12(S2):S26-35.
  21. Webster LR, Peppin JF, Murphy FT, Lu B, Tobias JK, Vanhove GF.  Efficacy, safety and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. Diabetes Research & Clinical Practice. 2011;93(2):187-97.
  22. Webster LR, Johnson FK, Stauffer J, Setnik B, Ciric S.  Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid usersDrugs in R&D. 2011;11(3):259-275.
  23. Webster LR, Brewer R, Morris D, Cleveland JM, Setnik B. Opioid titration and conversion in patients receiving morphine sulfate and naltrexone hydrochloride extended release capsules. Postgraduate Medicine. 2011;123(5):155-64.
  24. Yancey-Wrona J, Dallaire B, Bilsky E, Bath B, Burkart J, Webster LR, Maqiera D, Yang X, Phelps M, Sadee W. 6β-Naltrexol, a peripherally selective opioid antagonist that inhibits against morphine-induced slowing of gastrointestinal transit: an exploratory study. Pain Medicine. 2011;12(12):1727-1737.
  25. Webster LR, Fine PG. Review and critique of opioid rotation practices and associated risks of toxicityPain Medicine. 2012;13(4):562-570.
  26. Webster LR, Fine PG. Overdose deaths demand a new paradigm for opioid rotationPain Medicine. 2012;13(4):571-574.
  27. Webster LR, Rolleri RL, Pixton GC, Sommerville KW. Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCI-niacin tablets compared to oxycodone alone in nondependent recreational opioid users. Substance Abuse & Rehabilitation. 2012;3(1):101-13.
  28. Kalliomaki J, Segerdahl M, Webster L, Reimfelt A, Huizar K, Annas P, Karlsten R, Quiding H.  Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removalScandinavian Journal of Pain.
  29. Reisfield G, Webster LBenzodiazepines in long-term opioid therapyPain Medicine.  2013;14(10):1441-6.
  30. Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tak J.  Naloxegol for opioid-induced constipation in patients with noncancer painNew England Journal of Medicine. 2014;370(25):2387-96.
  31. Soergel DG, Subach RA, Burnham N, Lark MW, James IE, Sadler BM, Skobieranda F, Violin JD, Webster LRBiased agonism of the mu opioid receptor by TRV130 inceases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled crossover study in healthy volunteers. Pain.  2014;155(9):1829-35.
  32. Webster L, Chey WD, Tack J, Lappalainen J, Diva U, Sostek M. Randomised clinical trial: long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipationAlimentary Pharmacology & Therapeutics; 2014;41(7):771-9.
  33. Webster LR, Smith MD, Mackin S, Iverson M. Comparative effects of morning vs evening doses of extended-release hydromorphone on sleep physiology in patients with low back pain: a pilot study. Pain Medicine. 2014; doi: 10.1111/pme.12577.
  34. Passik SD, Webster LR. Opioid analgesics: does potency matter? The Journal of Opioid Management. 2014;10(4):263-76.
  35. Webster LR, Markman J. Medical management of chronic low back pain: efficacy and outcomes. Neuromodulation: Technology at the Neural Interface. 2014;17(S2):S18-23.
  36. Camilleri M, Drossman DA, Becker G, Webster LR, Davies AN, Mawe GM. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterology & Motility. 2014;26(10);1386-95.
  37. Webster LR. The relationship between the mechanisms of action and safety profiles of intrathecal morphine and Ziconotide. Pain Medicine. 2014; DOI: 10.1111/pme.12666.
  38. Webster L, Reisfield G, Dasgupta N. Eight principles for safer opioid prescribing and cautions with benzodiazepines. Postgraduate Medicine. 2015;127(1):27-32.
  39. Devarakonda K, Kostenbader K, Zheng Y, Mongtomery JB, Barrett T, Young JL, Webster LR. Human abuse potential of immediate-release/extended-release versus immediate-release hydrocodone bitartrate/acetaminophen: a randomized controlled trial in recreational users of prescription opioids. Postgraduate Medicine. 2015;127(1):13-21.
  40. Joseph D, Schobelock M, Risenberg R, Vince B, Webster L, Adeniji A, Elgadi M, Huang F. Effect of steady-state Faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine/naloxone in subjects on stable addiction management therapy. Antimicrobal Agents & Chemotherapy. 2015;59(1):498-504.
  41. Webster L. APhA2015 abstracts of contributed papers. The Journal of American Pharmacists Association. 2015;55(2):113-263.
  42. Schatman ME, Webster LR. The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability. Journal of Pain Research. 2015;2015(8):153-58.
  43. Webster LR, Brenner DM, Barrett AC, Paterson C, Bortey E, Forbes WP. Analysis of opioid-mediated analgesia in phase 3 studies of methylnaltrexone for opioid-induced constipation in patients with chronic non-cancer pain. Journal of Pain Research. 2015:8 771-780.
  44. Lipman A, Webster L. The economic impact of opioid use in the management of chronic non-malignant pain. Journal of Managed Care & Specialty Pharmacy.  2015 Oct;21(10):891-9.
  45. Jamal MM, Adams AB, Jansen JP, Webster LR. A randomized, placebo-controlled trial of Lubiprostone for opioid-induced constipation in chronic noncancer pain. American Journal of Gastroenterology. 2015; Advance online publication April, 28 2015; doi: 10.1038/ajg.2015.106.
  46. Morton T, Devarakonda K, Kostenbader K, Mongtomery J, Barrett T, Webster L. Correlation of subjective effects with sytematic opioid exposure from fixed-dose combinations of hydrocodone/acetaminophen in recreational users of prescription drugs: a randomized controlled trial. Pain Medicine. 2015; Advance online publication August 25, 2015; doi:10.1111/pme.12884.
  47. Webster L, M Brennan, L Kwong, R Levandowski, J Gudin. Opioid abuse-deterrent strategies: role of clinicians in acute pain managementPostgraduate Medicine. 3 Dec 2015, At: 12:26.
  48. Webster L, Finn A, Kirby T, Xiang Q. Low-dose naloxone provides an abuse-deterrent effect to buprenorphine. Journal of Pain Research. 2015 Nov 4;8:791-798.
  49. Webster L, Grabois M. Current Regulations Related to Opioid Prescribing. PM&R Pain Supplement. November 2015 Volume 7, Issue 11, Supplement, Pages S236-S247.
  50. Webster L, Kopecky E, Smith M, Fleming A. A Randomized, Double-blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of Xtampza ER™, a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. Pain Medicine. 2015; 0: 1-19; doi: 10.1093/pm/pnv020.
  51. Setnik B, Pixton GC, Webster LR. Safety profile of extended-release morphine sulfate with sequestered naltrexone hydrochloride in older patients: pool analysis of three clinical trials. Current Medical Research & Opinion.  2015; doi: 10.1185/03007995.2015.1131153.
  52. Webster L, Gruener D, Kirby T, Xiang Q, Tzanis E, Finn A. Evaluation of the tolerability of switching patients on chronic full μ -opioid agonist therapy to buccal buprenorphinePain Medicine 2016; 0: 1-9; doi 10.1093/pm/pnv110.
  53. Viscusi ER, Webster L, Kuss M, Daniels S, Bolognese JA, Zuckerman S, Soergel DG, Subach RA, Cook E, Skobieranda F. A Randomized, Phase 2 Study Investigating TRV130, a Biased Ligand of the µ-opioid Receptor, for the Intravenous Treatment of Acute Pain. PAIN 2016 Jan;157(1):264-72. doi: 10.1097/j.pain.0000000000000363.
  54. Setnik B, Roland CL, Goli V, Pixton GC, Levy-Cooperman N, Smith I, Webster L. Self-reports of prescription opioid abuse and diversion among recreational opioid users in a Canadian and a United States city. J Opioid Manag. 2015;11(6):463-73.
  55. Argoff CE, Brennan MJ, Camilleri M, Davies A, Fudin J, Galluzzi KE, Gudin J, Lembo A, Stanos SP, Webster LR. Consensus recommendations on initiating prescription therapies for opioid-induced constipation. Pain Med. 2015;16(12):2324-2337.



Get the latest news and thoughts about pain sent directly to you.